Meet the Start-ups

Amar Kamat | Founder & CEO | Sencilia

Amar M. Kamat, Ph.D., is the founder and CEO of Sencilia, an early-stage MedTech startup that develops sensor technology to improve the safety of drug delivery in neonatal and pediatric intensive care. Amar obtained his doctorate in Engineering Science and Mechanics from the Pennsylvania State University, and has previously worked for Intel Corp. (USA) and BASF SE (Germany) before co-founding Sencilia in 2021. He has been the recipient of several awards, such as the DAAD research fellowship (2015), the 'RUG FSE best postdoc award' (2020), and the LUMO Labs Draper Spring Pitch prize (2023). In addition to his role at Sencilia, Amar is also a guest researcher at the University of Groningen, and has (co-)authored over 30 peer-reviewed scientific publications (1100+ citations, h-index = 15).

About Sencilia

Up to 60% of intravenous (IV) infusions show flow rate errors, heightening the risk of accidental over/under dosage with serious clinical consequences (e.g. neurodevelopmental impairment) for neonatal and pediatric patients. To address this clinical problem, Sencilia (an academic startup from the University of Groningen) is developing a first-of-its-kind sensor technology that continuously and non-invasively monitors the status of the infusion, and alerts NICU/PICU clinicians instantly (99% faster than the standard of care) whenever any potential over/under dosage is detected. Sencilia's vision is to be the first and market-leading provider of IV infusion monitoring technology, thereby becoming the standard of care in IV drug administration by 2030.